Dates

Press releases

May 13, 2009

Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy

April 23, 2009

Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication

October 24, 2008

Addrenex Pharmaceuticals initiates phase 2 trial on its novel hypertension drug, ADX415

September 10, 2008

Addrenex Pharmaceuticals Announces Positive Phase III
Clinical Results for Clonicel to treat ADHD

August 19, 2008

Addrenex Pharmaceuticals’ New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation

July 1, 2008

Sciele Pharma Signs Agreement with Addrenex Pharmaceuticals To Develop and Market ADX415 for the Treatment of Hypertension

July 1, 2008

Addrenex Pharmaceuticals licenses new compound to Sciele Pharma for the treatment of hypertension and other potential indications

June 3, 2008

SCIELE PHARMA ANNOUNCES THAT ADDRENEX HAS COMPLETED ENROLLMENT OF PIVOTAL PHASE III TRIAL FOR CLONICEL FOR ADHD

April 22, 2008

SCIELE PHARMA ANNOUNCES FDA ACCEPTANCE OF NDA FOR ADDRENEX PHARMACEUTICALS' CLONIBID TO TREAT HYPERTENSION

February 20, 2008

Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension

February 20, 2008

Sciele and Addrenex Announce NDA Submission for CloniBid to Treat Hypertension

December 18, 2007

Local Start-Up Acquires Rights to Large Portfolio of Potential New Drugs Through License Agreement with the University of Nebraska Medical Center

October 30, 2007

Multicenter Study Tests Hypertension Drug to Calm the “H” in ADHD
“Hyper” has same root cause in hypertension and hyperactivity, study proposes.

October 30, 2007

Sciele Pharma and Addrenex Announce Initiation of Pivotal Phase III Trials for Clonicel for ADHD

July 17, 2007

PHARMACEUTICAL STARTUP SIGNS $6 MILLION DEAL IN ITS FIRST YEAR

July 12, 2007

Sciele Pharma Signs Agreement with Addrenex Pharmaceuticals to Market Clonicel®

Dates

Media Coverage

April 24, 2009

ADHD drug shines in final trial for Addrenex, Sciele
By The News & Observer

July 2, 2008

Durham, Atlanta companies partner. Drug venture could top $200 million
By The News & Observer

July 1, 2008

Addrenex lands deal worth as much as $27M
By Triangle Business Journal

May 30, 2008

Addrenex aims for fast track, Relatively young for drug company, it plans to create drugs to counter adrenaline
By The News & Observer

May 30, 2008

Drug research offers family new choice
By The News & Observer

December 18, 2007

UNMC licenses drugs to North Carolina Triangle Company
By The Lincoln Journal Star

December 18, 2007

Startup Addrenex Licenses Drug Technology from University of Nebraska
By WRAL.com

December 19, 2007

BRIEF: Addrenex to test potential medicines
By BusinessWeek

July 19, 2007

“Idea for pill gets new backer” - Hypertension, ADHD are targets
By The News & Observer